LEO 130852A + clobetasol propionate

LEO 130852A + clobetasol propionate is a topical pharmaceutical combination product. **LEO 130852A** is an experimental or investigational agent developed by LEO Pharma, most likely representing a novel compound or formulation in development, but no detailed public data on its chemical nature, class, or mechanism could be found. **Clobetasol propionate** is a highly potent synthetic corticosteroid used for its strong anti-inflammatory, antipruritic, and vasoconstrictive effects in the treatment of corticosteroid-responsive dermatoses, particularly moderate to severe plaque psoriasis. The combination suggests a strategy to enhance, complement, or modify the effects of clobetasol propionate for dermatological conditions. For clobetasol propionate, the mechanism of action is via strong agonism of the glucocorticoid receptor, leading to inhibition of pro-inflammatory mediators (such as phospholipase A2, prostaglandins, and leukotrienes), reduced leukocyte migration, and suppression of the immune response. The specific contribution and mechanism for LEO 130852A remain unpublished in publicly available detailed sources as of September 2025[1][2][3][4].